Clinical Trial Update: Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of bendamustine with bortezomib and pegylated liposomal doxorubicin in multiple myeloma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bendamustine (Bendamustine)
• Bortezomib (bortezomib)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Sherif Farag, MB, BS | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-10-06